Literature DB >> 31493190

Cytotoxic and antiproliferative effects of thymoquinone on rat C6 glioma cells depend on oxidative stress.

N G Krylova1, M S Drobysh2, G N Semenkova2, T A Kulahava3, S V Pinchuk4, O I Shadyro2.   

Abstract

Thymoquinone (TQ) is a highly perspective chemotherapeutic agent against gliomas and glioblastomas because of its ability to cross the blood-brain barrier and its selective cytotoxicity for glioblastoma cells compared to primary astrocytes. Here, we tested the hypothesis that TQ-induced mild oxidative stress provokes C6 glioma cell apoptosis through redox-dependent alteration of MAPK proteins. We showed that low concentrations of TQ (20-50 μM) promoted cell-cycle arrest and induced hydrogen peroxide generation as a result of NADH-quinone oxidoreductase 1-catalyzed two-electron reduction of this quinone. Similarly, low concentrations of TQ efficiently conjugated intracellular GSH disturbing redox state of glioma cells and provoking mitochondrial dysfunction. We demonstrated that high concentrations of TQ (70-100 μM) induced reactive oxygen species generation due to its one-electron reduction. TQ provoked apoptosis in C6 glioma cells through mitochondrial potential dissipation and permeability transition pore opening. The identified TQ modes of action on C6 glioma cells open up the possibility of considering it as a promising agent to enhance the sensitivity of cancer cells to standard chemotherapeutic drugs.

Entities:  

Keywords:  Apoptosis; Glioma; Mitochondrial dysfunction; Reactive oxygen species; Thymoquinone

Mesh:

Substances:

Year:  2019        PMID: 31493190     DOI: 10.1007/s11010-019-03622-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  51 in total

1.  Role of quinone moiety as antitumour agents: a review.

Authors:  Z S Saify; N Mushtaq; F Noor; S Takween; M Arif
Journal:  Pak J Pharm Sci       Date:  1999-07       Impact factor: 0.684

Review 2.  Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma.

Authors:  Divya Khosla
Journal:  Ann Transl Med       Date:  2016-02

Review 3.  Thymoquinone and its therapeutic potentials.

Authors:  Sara Darakhshan; Ali Bidmeshki Pour; Abasalt Hosseinzadeh Colagar; Sajjad Sisakhtnezhad
Journal:  Pharmacol Res       Date:  2015-03-28       Impact factor: 7.658

Review 4.  Survival in glioblastoma: a review on the impact of treatment modalities.

Authors:  P D Delgado-López; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2016-03-10       Impact factor: 3.405

Review 5.  Drug resistance in glioblastoma: a mini review.

Authors:  Catherine P Haar; Preetha Hebbar; Gerald C Wallace; Arabinda Das; William A Vandergrift; Joshua A Smith; Pierre Giglio; Sunil J Patel; Swapan K Ray; Naren L Banik
Journal:  Neurochem Res       Date:  2012-01-10       Impact factor: 3.996

6.  Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells.

Authors:  Resham Lal Gurung; Shi Ni Lim; Aik Kia Khaw; Jasmine Fen Fen Soon; Kirthan Shenoy; Safiyya Mohamed Ali; Manikandan Jayapal; Swaminathan Sethu; Rajamanickam Baskar; M Prakash Hande
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

Review 7.  The anticancer effects of vitamin K.

Authors:  Davis W Lamson; Steven M Plaza
Journal:  Altern Med Rev       Date:  2003-08

8.  Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.

Authors:  Christine Jungk; Despina Chatziaslanidou; Rezvan Ahmadi; David Capper; Justo Lorenzo Bermejo; Janina Exner; Andreas von Deimling; Christel Herold-Mende; Andreas Unterberg
Journal:  BMC Cancer       Date:  2016-02-10       Impact factor: 4.430

9.  Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells.

Authors:  Ira O Racoma; Walter Hans Meisen; Qi-En Wang; Balveen Kaur; Altaf A Wani
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

Review 10.  Targeting autophagy to sensitive glioma to temozolomide treatment.

Authors:  Yuanliang Yan; Zhijie Xu; Shuang Dai; Long Qian; Lunquan Sun; Zhicheng Gong
Journal:  J Exp Clin Cancer Res       Date:  2016-02-02
View more
  6 in total

Review 1.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

2.  Investigation of cellular effects of thymoquinone on glioma cell.

Authors:  Eray Metin Guler; Behice Hande Sisman; Abdurrahim Kocyigit; Mustafa Aziz Hatiboglu
Journal:  Toxicol Rep       Date:  2021-01-04

Review 3.  Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis.

Authors:  Mina Homayoonfal; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-03-02       Impact factor: 5.787

4.  IP-Se-06, a Selenylated Imidazo[1,2-a]pyridine, Modulates Intracellular Redox State and Causes Akt/mTOR/HIF-1α and MAPK Signaling Inhibition, Promoting Antiproliferative Effect and Apoptosis in Glioblastoma Cells.

Authors:  Daniela C Dos Santos; Jamal Rafique; Sumbal Saba; Valdelúcia M A S Grinevicius; Danilo W Filho; Ariane Zamoner; Antonio L Braga; Rozangela C Pedrosa; Fabiana Ourique
Journal:  Oxid Med Cell Longev       Date:  2022-03-22       Impact factor: 6.543

Review 5.  Potential targets and treatments affect oxidative stress in gliomas: An overview of molecular mechanisms.

Authors:  Shiyu Liu; Lihua Dong; Weiyan Shi; Zhuangzhuang Zheng; Zijing Liu; Lingbin Meng; Ying Xin; Xin Jiang
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

Review 6.  Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.

Authors:  Ravi Raj Pal; Vasundhara Rajpal; Priya Singh; Shubhini A Saraf
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.